Evidence map›Paper›PMID 40083443›Full record

ArticleEClinicalMedicine2025

The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis.

Lottie Brown, Lena Tschiderer, Alexandre Alanio, Rosemary A Barnes, Sharon C-A Chen, Massimo Cogliati, Mario Cruciani, J Peter Donnelly, Ferry Hagen, Catriona Halliday and 19 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. OesophagealMedical mycology case reports · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Observational
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Lottie BrownSt George's Hospital, St George's NHS Foundation Trust, London, UK.
Lena TschidererInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria.
Alexandre AlanioInstitut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, F-75015, France.
Rosemary A BarnesSchool of Medicine, Cardiff University, Cardiff, UK.
Sharon C-A ChenCentre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clincial Pathology and Medical Research, New South Wales Pathology, Westmead Hospital and The University of Sydney, Sydney, Australia.
Massimo CogliatiMedical Mycology Laboratory, Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milano, Italy.
Mario CrucianiFungal PCR Initiative, A Working Group of the International Society of Human and Animal Mycology, Verona, Italy.
J Peter DonnellyEAPCRI Foundation, De Hoefkamp 1096, Nijmegen, 6545MD, the Netherlands.
Ferry HagenWesterdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
Catriona HallidayClinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research - New South Wales Health Pathology, Westmead Hospital, Westmead, NSW, Australia.
Lena KlingsporDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Katrien LagrouDepartment of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.
Willem MelchersDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Laurence MillonChrono-environnement UMR6249, CNRS, Franche-Comté University, Besançon, F-25000, France.
Florent MorioCHU de Nantes, Cibles et Médicaments des Infections et de l'Immunité, Nantes Université, IICiMed, UR1155, Nantes, 44000, France.
Elena SalvadorDepartment of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni, 5, Verona, 37024, Italy.
Giacomo StroffoliniDepartment of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni, 5, Verona, 37024, Italy.
Markus RuhnkeHelios Klinikum Aue, Klinik fürHämatologie/Onkologie & Palliativmedizin, Aue, Germany.
Stephanie ToepferInstitute for Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Karin van DijkDepartment of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.
Andrew M BormanUKHSA Mycology Reference Laboratory, Southmead Hospital, Bristol, UK.
María José BuitragoMycology Reference Laboratory, National Centre for Microbiology and CIBERINFEC, ISCIII -CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
Rebecca GortonDepartment of Infection Sciences, Health Services Laboratories, London, UK.
Jürgen LöffllerMedizinische Klinik II, Labor WÜ4i, Universitätsklinikum Würzburg, Germany.
Riina Rautemaa-RichardsonMycology Reference Centre Manchester and Department of Infectious Diseases, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK.
Boualem SendidINSERM U1285, CNRS UMR 8576, Université de Lille, CHU Lille, Institut de Microbiologie, Service de Parasitologie-Mycologie, Lille, F-59000, France.
Peter WilleitInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria.
P Lewis WhitePublic Health Wales Mycology Reference Laboratory and Cardiff University Centre for Trials Research, UHW, Cardiff, UK.
Michaela LacknerInstitute for Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This systematic review and meta-analysis aimed to examine the performance of polymerase chain reaction (PCR) assays for diagnosing mucormycosis. Methods: A standardised search was conducted from conception to December 3rd 2024 using PubMed, Embase, Global Health, and Cochrane library. Original studies that used PCR-based methods on any human specimen to diagnose mucormycosis were analysed for eligibility. Using a bivariate meta-analysis, the diagnostic performance of PCR was examined against the European Organisation for Research and Treatment of Cancer-Mycoses Study Group Education and Research Consortium 2020 (EORTC-MSGERC) definitions of proven and probable invasive mould disease, which was modified to include all patients at risk of mucormycosis. The study protocol was registered on the PROSPERO database (CRD42023478667). Findings: Of 4855 articles, a total of 30 met inclusion criteria, including 5920 PCR reactions on 5147 non-duplicate specimens from 819 cases of proven/probable mucormycosis and 4266 patients who did not meet the EORTC-MSGERC 2020 criteria. According to specimen type, sensitivity of PCR varied (p < 0.001) whereas specificity was similar (p = 0.662). Bronchoalveolar lavage fluid offered the highest sensitivity of 97.5% (95% CI 83.7-99.7%), specificity of 95.8% (95% CI 89.6-98.4%), positive likelihood ratio (LR+) of 23.5, and negative likelihood ratio (LR-) of 0.03. Tissue provided sensitivity of 86.4% (95% CI 78.9-91.5%), specificity of 90.6% (95% CI 78.1-96.3%), LR+ of 9.2, and LR- of 0.15. Blood provided reduced sensitivity of 81.6% (95% CI 70.1-89.4%), specificity of 95.5% (95% CI 87.4-98.5%), DOR of 95, LR+ of 18.3, and LR- of 0.19. Formalin-fixed paraffin-embedded specimens yielded the lowest sensitivity of 73.0% (95% CI 61.0-82.3%), highest specificity of 96.4% (CI 95% 87.5-99.0%), LR+ of 20.2, and LR- of 0.28. The covariates best explaining heterogeneity of the overall analysis were specimen type, study design (cohort Interpretation: This meta-analysis confirms the high performance of PCR for diagnosing mucormycosis and supports the instatement of PCR detection of free-DNA in blood, BALF and tissue into future updated definitions and diagnostic guidelines for mucormycosis. Funding: None.

Indexed as

DiagnosisFungalMucoralesMucormycosisPCR

Identifiers

PMID40083443
PMCPMC11905852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.